Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

NCT06215651 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cadonilimab and Lenvatinib

Interventions

DRUG: Cadonilimab lenvatinib

Sponsor

Peking Union Medical College Hospital